STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML

被引：0
|
作者：
Mauro, MJ [1 ]
Druker, BJ [1 ]
机构：
[1] Oregon Hlth Sci Univ, Portland, OR 97201 USA
来源：
LEUKEMIA | 2001年 / 15卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O23
引用
收藏
页码：488 / 488
页数：1
相关论文
共 50 条
  • [1] STI571: Targeting BCR-ABL as therapy for CML
    Mauro, MJ
    Druker, BJ
    ONCOLOGIST, 2001, 6 (03): : 233 - 238
  • [2] AN APPROACH TO OVERCOME BCR-ABL INDEPENDENT STI571 RESISTANCE IN CML
    Rabizadeh, E.
    Aviram, A.
    Belyaeva, I.
    Merkin, V.
    Avissar, N.
    Shaklai, M.
    Zimra, Y.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 131 - 131
  • [3] Bcr-Abl kinase inhibition as the basis of therapy for CML
    Druker, BJ
    Talpaz, M
    Resta, D
    Peng, B
    Buchdunger, E
    Ford, J
    Sawyers, CL
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 130 - 130
  • [4] Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571
    Corbin, AS
    Buchdunger, E
    Pascal, F
    Druker, BJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) : 32214 - 32219
  • [5] Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDCFR kinases
    Manley, PW
    Breitenstein, W
    Brüggen, J
    Cowan-Jacob, SW
    Furet, P
    Mestan, J
    Meyer, T
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (23) : 5793 - 5797
  • [6] Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)
    Wohlbold, L
    van der Kuip, H
    Miething, C
    Vornlocher, HP
    Knabbe, C
    Duyster, J
    Aulitzky, WE
    BLOOD, 2003, 102 (06) : 2236 - 2239
  • [7] BCR/ABL amplification in CML blast crisis following STI571 administration.
    Campbell, LJ
    Patsouris, C
    Rayeroux, KC
    Somana, K
    Januszewicz, H
    BLOOD, 2001, 98 (11) : 185B - 185B
  • [8] STI571 as a targeted therapy for CML
    O'Dwyer, ME
    Mauro, MJ
    Druker, BJ
    CANCER INVESTIGATION, 2003, 21 (03) : 429 - 438
  • [9] Serial molecular analysis of bcr-abl expression and chimerism status in CML patients following STI571 treatment.
    Gately, K
    Ryan, J
    McCann, S
    Howard, J
    Stallings, R
    Carroll, P
    Browne, P
    Conneally, E
    Lawler, M
    BRITISH JOURNAL OF CANCER, 2002, 86 : S88 - S89
  • [10] STI571 inhibition of BCR/ABL transformed cells is potentiated by hyperthermia.
    Antonucci, JV
    De Aos, I
    Oo, T
    Varticovski, L
    BLOOD, 2000, 96 (11) : 346A - 347A
12345